Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo.
paper
Cited
Public
Unavailable
- Authors
- Fisher, Ffolliott M; Estall, Jennifer L; Adams, Andrew C; Antonellis, Patrick J; Bina, Holly A; Flier, Jeffrey S; Kharitonenkov, Alexei; Spiegelman, Bruce M; Maratos-Flier, Eleftheria
- Year
- 2011
- Journal
- Endocrinology
- PMID
- 21712364
- DOI
- 10.1210/en.2011-0281
- PMCID
- PMC3138239
Fibroblast growth factor (FGF21) plays an important role in regulating hepatic oxidation of fatty acids and gluconeogenesis in response to fasting and during consumption of a ketogenic diet. However, the metabolic pathways through which FGF21 regulates hepatic function are not well defined. To identify the effects of FGF21 on the liver in vivo, we administered FGF21 to mice and analyzed acute effects on signaling and gene expression. We found that FGF21 acts directly on the liver to stimulate phosphorylation of fibroblast growth factor receptor substrate 2 and ERK1/2. Acute FGF21 treatment induced hepatic expression of key regulators of gluconeogenesis, lipid metabolism, and ketogenesis including glucose-6-phosphatase, phosphoenol pyruvate carboxykinase, 3-hydroxybutyrate dehydrogenase type 1, and carnitine palmitoyltransferase 1Ξ±. In addition, injection of FGF21 was associated with decreased circulating insulin and free fatty acid levels. FGF21 treatment induced mRNA and protein expression of peroxisome proliferator-activated receptor-Ξ³ coactivator (PGC-1Ξ±), suggesting that PGC-1Ξ± may play a role in regulating FGF21 action. However, studies using mice with liver-specific ablation of PGC-1Ξ± revealed the same regulation of gluconeogenic gene expression by FGF21 as seen in wild-type mice, indicating that PGC-1Ξ± is not necessary for the effect of FGF21 on glucose metabolism. These data demonstrate that FGF21 acts directly on the liver to modulate hepatic metabolism. The direct effects we examined are not dependent on PGC-1Ξ±. In addition, FGF21 treatment is associated with decreased serum insulin levels that my affect hepatic function.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| TypeΒ 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies. | Corrao S et al. | β | 2025 | β |
| UPRmt-regulated mitokines: novel strategies for myocardial injury repair. | Gao W et al. | β | 2025 | β |
| Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV. | Ramirez Bustamante CE et al. | β | 2024 | β |
| Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. | GarcΓa-MartΓnez P et al. | β | 2024 | β |
| Differential transcriptional profiles of vagal sensory neurons in female and male mice. | Jo YH | β | 2024 | β |
| Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network. | Li S et al. | β | 2024 | β |
| Gemigliptin mitigates TGF-Ξ²-induced renal fibrosis through FGF21-mediated inhibition of the TGF-Ξ²/Smad3 signaling pathway. | Byun JK et al. | β | 2024 | β |
| Lipid sensing by PPARΞ±: Role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting. | Fougerat A et al. | β | 2024 | β |
| Novel FGF21 analogues through structure-based optimization for therapeutic development. | Guo Y et al. | β | 2024 | β |
| Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. | Tian S et al. | β | 2024 | β |
| The Influence of Hyperglycemia on Liver Triglyceride Deposition in Partially Pancreatectomized Rats. | Bai XP et al. | β | 2024 | β |
| Thermoneutrality Inhibits Thermogenic Markers and Exacerbates Nonalcoholic Fatty Liver Disease in Mice. | Hao L et al. | β | 2024 | β |
| An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. | Lee E et al. | β | 2023 | β |
| Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role? | Vankrunkelsven W et al. | β | 2023 | β |
| FGF21 alleviates endothelial mitochondrial damage and prevents BBB from disruption after intracranial hemorrhage through a mechanism involving SIRT6. | Wang R et al. | β | 2023 | β |
| Signaling pathways and intervention for therapy of type 2 diabetes mellitus. | Cao R et al. | β | 2023 | β |
| Adherence to low carbohydrate diets and non-alcoholic fatty liver disease: a case control study. | Yaghoubi F et al. | β | 2022 | β |
| Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. | Ding H et al. | β | 2022 | β |
| FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. | SzczepaΕska E et al. | β | 2022 | β |
| FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk. | Chaffin AT et al. | β | 2022 | β |
| FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism. | SzczepaΕska E et al. | β | 2022 | β |
| Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients. | Corbee RJ et al. | β | 2022 | β |
| Fibroblast growth factor-21 improves insulin action in nonlactating ewes. | Lamb CL et al. | β | 2022 | β |
| Multi-organ FGF21-FGFR1 signaling in metabolic health and disease. | Kaur N et al. | β | 2022 | β |
| The potential function and clinical application of FGF21 in metabolic diseases. | Chen Z et al. | β | 2022 | β |
| Advances in Biological Functions and Clinical Studies of FGF21. | Lin W et al. | β | 2021 | β |
| Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. | Hua S et al. | β | 2021 | β |
| Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. | Ji Y et al. | β | 2021 | β |
| Effects of low-carbohydrate diet and ketogenic diet on glucose and lipid metabolism in type 2 diabetic mice. | Yang Z et al. | β | 2021 | β |
| Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects. | PΕatek T et al. | β | 2021 | β |
| FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction. | Diener JL et al. | β | 2021 | β |
| <i>Bifidobacterium adolescentis</i> Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. | Long X et al. | β | 2021 | β |
| Metabolic Messengers: FGF21. | Flippo KH et al. | β | 2021 | β |
| PPARΞ± agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. | Xu Y et al. | β | 2021 | β |
| Skeletal Muscle and Bone - Emerging Targets of Fibroblast Growth Factor-21. | Sun H et al. | β | 2021 | β |
| Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs its Signaling Pathways in Liver and Adipose Tissue in Mice | Liu X et al. | β | 2021 | β |
| Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice. | Liu XH et al. | β | 2021 | β |
| Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects. | Watanabe H et al. | β | 2020 | β |
| Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. | Byun S et al. | β | 2020 | β |
| FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | Tillman EJ et al. | β | 2020 | β |
| FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish. | Blanco AM et al. | β | 2020 | β |
| FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. | Keinicke H et al. | β | 2020 | β |
| Impact of Conventional and Atypical MAPKs on the Development of Metabolic Diseases. | Kassouf T et al. | β | 2020 | β |
| Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands. | Zhao M et al. | β | 2020 | β |
| Systemic effects of mitochondrial stress. | Bar-Ziv R et al. | β | 2020 | β |
| The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. | Geng L et al. | β | 2020 | β |
| Bile Acids as Metabolic Regulators and Nutrient Sensors. | Chiang JYL et al. | β | 2019 | β |
| Caspase-2 and p75 neurotrophin receptor (p75NTR) are involved in the regulation of SREBP and lipid genes in hepatocyte cells. | Pham DD et al. | β | 2019 | β |
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | Wang K et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges. | MartΓnez-Garza Γ et al. | β | 2019 | β |
| Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. | Su X et al. | β | 2019 | β |
| Going Back to the Biology of FGF21: New Insights. | Lewis JE et al. | β | 2019 | β |
| High-efficiency expression and secretion of human FGF21 in Bacillus subtilis by intercalation of a mini-cistron cassette and combinatorial optimization of cell regulatory components. | Li D et al. | β | 2019 | β |
| Interaction between the amount of dietary protein and the environmental temperature on the expression of browning markers in adipose tissue of rats. | AlemΓ‘n G et al. | β | 2019 | β |
| Maresin 1 Regulates Hepatic FGF21 in Diet-Induced Obese Mice and in Cultured Hepatocytes. | MartΓnez-FernΓ‘ndez L et al. | β | 2019 | β |
| MS-275 induces hepatic FGF21 expression via H3K18ac-mediated CREBH signal. | Zhang Q et al. | β | 2019 | β |
| Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. | Zarei M et al. | β | 2019 | β |
| The impact of keto-adaptation on exercise performance and the role of metabolic-regulating cytokines. | Sherrier M et al. | β | 2019 | β |
| The Klotho proteins in health and disease. | Kuro-O M | β | 2019 | β |
| Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. | Taliyan R et al. | β | 2019 | β |
| CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis. | Prentice KJ et al. | β | 2018 | β |
| Crosstalk mechanisms in hepatoprotection: Thyroid hormone-docosahexaenoic acid (DHA) and DHA-extra virgin olive oil combined protocols. | Valenzuela R et al. | β | 2018 | β |
| Cytochrome P450s and Alcoholic Liver Disease. | Lu Y et al. | β | 2018 | β |
| Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor Ξ³ coactivator-1Ξ±-deficient mice. | Fletcher JA et al. | β | 2018 | β |
| Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. | Pathak P et al. | β | 2018 | β |
| Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young mice. | Gasparin FRS et al. | β | 2018 | β |
| A combined docosahexaenoic acid-thyroid hormone protocol upregulates rat liver Ξ²-Klotho expression and downstream components of FGF21 signaling as a potential novel approach to metabolic stress conditions. | Vargas R et al. | β | 2017 | β |
| Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARΞ±-FGF21 axis. | Chen X et al. | β | 2017 | β |
| A Specific ChREBP and PPARΞ± Cross-Talk Is Required for the Glucose-Mediated FGF21 Response. | Iroz A et al. | β | 2017 | β |
| A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug? | Maniar K et al. | β | 2017 | β |
| Dietary treatment of fatty liver: High dietary protein content has an antisteatotic and antiobesogenic effect in mice. | Garcia Caraballo SC et al. | β | 2017 | β |
| Fasting-induced hormonal regulation of lysosomal function. | Chen L et al. | β | 2017 | β |
| FGF19, FGF21, and an FGFR1/Ξ²-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. | Lan T et al. | β | 2017 | β |
| FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process. | Salminen A et al. | β | 2017 | β |
| FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans. | SΓΈberg S et al. | β | 2017 | β |
| FGF23-Ξ±Klotho as a paradigm for a kidney-bone network. | Kuro-O M et al. | β | 2017 | β |
| Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. | Staiger H et al. | β | 2017 | β |
| Fibroblast growth factor 21 night watch: advances and uncertainties in the field. | Kharitonenkov A et al. | β | 2017 | β |
| Hepatic Crtc2 controls whole body energy metabolism via a miR-34a-Fgf21 axis. | Han HS et al. | β | 2017 | β |
| Impact of Fibroblast Growth Factors 19 and 21 in Bariatric Metabolism. | Patton A et al. | β | 2017 | β |
| Induction of fibroblast growth factor 21 does not require activation of the hepatic X-box binding protein 1 in mice. | Olivares S et al. | β | 2017 | β |
| Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. | Lin X et al. | β | 2017 | β |
| N-3 polyunsaturated fatty acids increase hepatic fibroblast growth factor 21 sensitivity via a PPAR-Ξ³-Ξ²-klotho pathway. | Yang W et al. | β | 2017 | β |
| Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1Ξ± Signaling Axis. | Wu H et al. | β | 2017 | β |
| The role of fibroblast growth factor 21 in atherosclerosis. | Kokkinos J et al. | β | 2017 | β |
| A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. | Woolsey SJ et al. | β | 2016 | β |
| An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. | Lee JH et al. | β | 2016 | β |
| Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles. | Jeon JY et al. | β | 2016 | β |
| Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. | Finan B et al. | β | 2016 | β |
| CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis. | Park JG et al. | β | 2016 | β |
| Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations. | Fletcher JA et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus. | So WY et al. | β | 2016 | β |
| Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting. | Antonellis PJ et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. | Jin L et al. | β | 2016 | β |
| Hepatic global DNA and peroxisome proliferator-activated receptor alpha promoter methylation are altered in peripartal dairy cows fed rumen-protected methionine. | Osorio JS et al. | β | 2016 | β |
| Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. | Donate-Correa J et al. | β | 2016 | β |
| Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway. | Yu D et al. | β | 2016 | β |
| iTRAQ-based proteomic analysis reveals alterations in the liver induced by restricted meal frequency in a pig model. | Liu J et al. | β | 2016 | β |
| Molecular hydrogen stimulates the gene expression of transcriptional coactivator PGC-1Ξ± to enhance fatty acid metabolism. | Kamimura N et al. | β | 2016 | β |
| Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds. | PΓ©rez-MartΓ A et al. | β | 2016 | β |
| Overexpression of Ξ²-Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity. | Samms RJ et al. | β | 2016 | β |
| Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state. | Guan D et al. | β | 2016 | β |
| Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate. | Sahuri-Arisoylu M et al. | β | 2016 | β |
| Role of fibroblast growth factors in organ regeneration and repair. | El Agha E et al. | β | 2016 | β |
| The FGF21-adiponectin axis in controlling energy and vascular homeostasis. | Hui X et al. | β | 2016 | β |
| The FGF21 Receptor Signaling Complex: KlothoΞ², FGFR1c, and Other Regulatory Interactions. | Kilkenny DM et al. | β | 2016 | β |
| The regulation of FGF21 gene expression by metabolic factors and nutrients. | Erickson A et al. | β | 2016 | β |
| Understanding the Physiology of FGF21. | Fisher FM et al. | β | 2016 | β |
| Alterations in Hepatic FGF21, Co-Regulated Genes, and Upstream Metabolic Genes in Response to Nutrition, Ketosis and Inflammation in Peripartal Holstein Cows. | Akbar H et al. | β | 2015 | β |
| Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. | Douris N et al. | β | 2015 | β |
| Circulating FGF19 and FGF21 surge in early infancy from infra- to supra-adult concentrations. | SΓ‘nchez-Infantes D et al. | β | 2015 | β |
| Clock circadian regulator (CLOCK) gene network expression patterns in bovine adipose, liver, and mammary gland at 3 time points during the transition from pregnancy into lactation. | Wang M et al. | β | 2015 | β |
| Dual effects of fibroblast growth factor 21 on hepatic energy metabolism. | Samms RJ et al. | β | 2015 | β |
| Endoplasmic reticulum stress induces up-regulation of hepatic Ξ²-Klotho expression through ATF4 signaling pathway. | Dong K et al. | β | 2015 | β |
| FGF21 and the late adaptive response to starvation in humans. | Fazeli PK et al. | β | 2015 | β |
| FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice. | Stemmer K et al. | β | 2015 | β |
| FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties. | Kharitonenkov A et al. | β | 2015 | β |
| Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. | Zhang J et al. | β | 2015 | β |
| Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. | Lin Z et al. | β | 2015 | β |
| Fibroblast Growth Factor Signaling in Metabolic Regulation. | Nies VJ et al. | β | 2015 | β |
| Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. | Domouzoglou EM et al. | β | 2015 | β |
| Homeostasis, inflammation, and disease susceptibility. | Kotas ME et al. | β | 2015 | β |
| Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue. | Asrih M et al. | β | 2015 | β |
| Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21. | Assini JM et al. | β | 2015 | β |
| Of mice and men: novel insights regarding constitutive and recruitable brown adipocytes. | Townsend KL et al. | β | 2015 | β |
| Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. | Gallego-Escuredo JM et al. | β | 2015 | β |
| Protein-dependent regulation of feeding and metabolism. | Morrison CD et al. | β | 2015 | β |
| Resistance to the Beneficial Metabolic Effects and Hepatic Antioxidant Defense Actions of Fibroblast Growth Factor 21 Treatment in Growth Hormone-Overexpressing Transgenic Mice. | Boparai RK et al. | β | 2015 | β |
| Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. | Owen BM et al. | β | 2015 | β |
| ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. | Wan XS et al. | β | 2014 | β |
| FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases. | Itoh N | β | 2014 | β |
| FGF21-based pharmacotherapy--potential utility for metabolic disorders. | Gimeno RE et al. | β | 2014 | β |
| FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARΞ³-LXRΞ± pathway in THP1 macrophage-derived foam cells. | Lin XL et al. | β | 2014 | β |
| FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway. | Lin X et al. | β | 2014 | β |
| FGF21 is an endocrine signal of protein restriction. | Laeger T et al. | β | 2014 | β |
| Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. | Domouzoglou EM et al. | β | 2014 | β |
| Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. | Brahma MK et al. | β | 2014 | β |
| Genetic models of PGC-1 and glucose metabolism and homeostasis. | Rowe GC et al. | β | 2014 | β |
| Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. | Cyphert HA et al. | β | 2014 | β |
| Head over hepatocytes for FGF21. | Potthoff MJ et al. | β | 2014 | β |
| Integrated physiology and systems biology of PPARΞ±. | Kersten S | β | 2014 | β |
| Interplay between FGF21 and insulin action in the liver regulates metabolism. | Emanuelli B et al. | β | 2014 | β |
| Inventing new medicines: The FGF21 story. | Kharitonenkov A et al. | β | 2014 | β |
| Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor Ξ± to regulate metabolic hormone FGF21. | Kim H et al. | β | 2014 | β |
| Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. | Lees EK et al. | β | 2014 | β |
| Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies. | Antonellis PJ et al. | β | 2014 | β |
| Roles of FGFs as Adipokines in Adipose Tissue Development, Remodeling, and Metabolism. | Ohta H et al. | β | 2014 | β |
| Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. | Mutanen A et al. | β | 2014 | β |
| Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. | Johnson CL et al. | β | 2014 | β |
| Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. | Keipert S et al. | β | 2014 | β |
| The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. | Cantley J | β | 2014 | β |
| Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. | Lin Z et al. | β | 2013 | β |
| Adverse effects of excessive leucine intake depend on dietary protein intake: a transcriptomic analysis to identify useful biomarkers. | Imamura W et al. | β | 2013 | β |
| An endocrine role for brown adipose tissue? | Villarroya J et al. | β | 2013 | β |
| A novel approach to improve the function of FGF21. | Smith R et al. | β | 2013 | β |
| Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. | Kim KH et al. | β | 2013 | β |
| Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. | Choi SE et al. | β | 2013 | β |
| Fgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. | Murata Y et al. | β | 2013 | β |
| FGF21 mediates the lipid metabolism response to amino acid starvation. | De Sousa-Coelho AL et al. | β | 2013 | β |
| Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. | Woo YC et al. | β | 2013 | β |
| Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. | Adams AC et al. | β | 2013 | β |
| Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. | Hu MC et al. | β | 2013 | β |
| Metabolic hormone FGF21 is induced in ground squirrels during hibernation but its overexpression is not sufficient to cause torpor. | Nelson BT et al. | β | 2013 | β |
| Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. | Camacho RC et al. | β | 2013 | β |
| Retinoic acid receptor Ξ² stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. | Li Y et al. | β | 2013 | β |
| Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history. | Wang D et al. | β | 2013 | β |
| Stressed Liver and Muscle Call on Adipocytes with FGF21. | Luo Y et al. | β | 2013 | β |
| Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. | Angelin B et al. | β | 2012 | β |
| Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice. | Wang ZQ et al. | β | 2012 | β |
| Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. | Cicione C et al. | β | 2012 | β |
| Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. | Potthoff MJ et al. | β | 2012 | β |
| FGF21 regulates PGC-1Ξ± and browning of white adipose tissues in adaptive thermogenesis. | Fisher FM et al. | β | 2012 | β |
| FGF21 requires Ξ²klotho to act in vivo. | Adams AC et al. | β | 2012 | β |
| Fundamentals of FGF19 & FGF21 action in vitro and in vivo. | Adams AC et al. | β | 2012 | β |
| Genomic and metabolic responses to methionine-restricted and methionine-restricted, cysteine-supplemented diets in Fischer 344 rat inguinal adipose tissue, liver and quadriceps muscle. | Perrone CE et al. | β | 2012 | β |
| Identification of novel Sp1 targets involved in proliferation and cancer by functional genomics. | Oleaga C et al. | β | 2012 | β |
| Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. | Goetz R et al. | β | 2012 | β |
| Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. | Schugar RC et al. | β | 2012 | β |
| Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. | Fletcher JA et al. | β | 2012 | β |
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. | Adams AC et al. | β | 2012 | β |
| Thioesterase superfamily member 2/acyl-CoA thioesterase 13 (Them2/Acot13) regulates hepatic lipid and glucose metabolism. | Kang HW et al. | β | 2012 | β |
| Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. | Samson SL et al. | β | 2011 | β |